戻る
「早戻しボタン」を押すと検索画面に戻ります。

今後説明を表示しない

[OK]

コーパス検索結果 (1語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 iers such as SIGCAFKILGY(-cysteamine) [SIGC(-cysteamine)].
2 to produce pantothenic acid (vitamin B5) and cysteamine.
3 pionic acid, 4-pyridinylethanemercaptan, and cysteamine.
4 increased the production of hypotaurine from cysteamine.
5 o the enzymes cysteine dioxygenase (CDO) and cysteamine (2-aminoethanethiol) dioxygenase (ADO).
6 -cysteine with isosteric substrate analogues cysteamine, 3-mercaptopropionic acid, and propane thiol
7                                        Fresh cysteamine (600 mg/kg) was added to drinking water daily
8 pered our understanding of the metabolism of cysteamine, a product of the constitutive degradation of
9                 Two types of cationic AuNPs, cysteamine and CTAB capped, were compared to achieve max
10                                              Cysteamine and cystamine also augmented basal intracellu
11 ioprotectants including human serum albumin, cysteamine and glycerol were evaluated.
12 However, experimental studies with the thiol cysteamine and its disulfide cystamine have demonstrated
13 e or withanolide A, was highly reactive with cysteamine and rapidly succumbed to irreversible nucleop
14  therefore studied the actions of cystamine, cysteamine and several reference thiol agents as cytopro
15 ell-known radioprotective agents L-cysteine, cysteamine, and 2-[(aminopropyl)amino]ethanethiol (WR-10
16        Intracellular thiols (e.g., cysteine, cysteamine, and glutathione) can trigger the release of
17 enal transplantation, administration of oral cysteamine, and time and cause of death.
18 t assay using 14C-(C-1)-labeled L-serine and cysteamine as substrates, counting the thialysine produc
19                       Patients received oral cysteamine bitartrate (60 mg/kg per day) and N-acetylcys
20 ndings suggest that combination therapy with cysteamine bitartrate and N-acetylcysteine is associated
21  aimed to assess whether combination of oral cysteamine bitartrate and N-acetylcysteine is beneficial
22 olled trial to determine whether 52 weeks of cysteamine bitartrate delayed release (CBDR) reduces the
23  two patients, which disappeared when liquid cysteamine bitartrate was replaced with capsules.
24 s, we evaluated the antifibrotic efficacy of cysteamine bitartrate, an antioxidant therapy for patien
25  the sensitive voltammetric determination of cysteamine (CA), nicotinamide adenine dinucleotide (NADH
26  such as acetone, acetaldehyde, isoprene, or cysteamine can be detected in the breath gas with SPI, R
27        The large difference in the yields of cysteamine can be used to explain the drugs' different t
28 sulfonic acid, mercapto-propionyglycine, and cysteamine can directly sequester aldehydes.
29                         The sensor relies on cysteamine capped gold nanoparticles (N-AuNPs) covalentl
30 protection using a recently developed Trolox-cysteamine cocktail.
31 of autophagy activators involving fatty acid cysteamine conjugates.
32 Lipophilic thiols such as mercaptoethanol or cysteamine could partially reverse the CCl4-induced calc
33                           By functionalizing cysteamine (CS)-stabilized gold nanoparticles (CS-AuNPs)
34 , separation-free and selective detection of cysteamine (CSH).
35                                       Copper Cysteamine (Cu-Cy) is a new photosensitizer and a novel
36 yer principle by modifying Au electrode with cysteamine (Cys) and immobilization of ferrocene cored p
37 lized on the Au/SPE previously aminated with cysteamine (Cys) by self-assembling monolayer technique.
38                     In electrode fabrication cysteamine (Cys) was the first agent covalently linked o
39 nic acid (cysteine without the amino group), cysteamine (cysteine without the carboxylic acid), or me
40         The reaction was highly specific for cysteamine; cysteine was not oxidized by the enzyme, and
41      Decrease of lysosomal cystine levels by cysteamine did not rescue mTORC1 activation in these cel
42 raldehyde crosslinking and functionalized by cysteamine dihydrochloride.
43 combinant protein, ADO exhibited significant cysteamine dioxygenase activity in vitro.
44 ggest that ADO is responsible for endogenous cysteamine dioxygenase activity.
45 ly of enzymes includes cysteine dioxygenase, cysteamine dioxygenase, mercaptosuccinate dioxygenase, a
46 he protein, relatively little is known about cysteamine dioxygenase.
47 ned carbon chain and lacks a carboxyl group, cysteamine displays a catalytic efficiency (kcat/Km) wit
48                             However, because cysteamine does not correct all complications of cystino
49  modified with a self-assembled monolayer of cysteamine followed by cross-linking with glutaraldehyde
50 ations and deaths than patients who received cysteamine for fewer than 8 years.
51 to be ineffective at zinc ejection, although cysteamine formed a transient complex with the zinc fing
52 d that the steady state percentage yields of cysteamine from cystamine and pantethine during the tran
53 vate, homocysteine (from cystathionine), and cysteamine (from S-aminoethyl-L-cysteine).
54  In the case of the bacterial member ELIC, a cysteamine-gated channel from Erwinia chrisanthemi, a st
55 abeled diketide-SNAC 2 and N-[1-(14)C-acetyl]cysteamine gave a k(exch) of 0.15 +/- 0.06 min(-)(1), wi
56                  We report herein the use of cysteamine-graphene oxide modified gold microelectrode a
57 amine) specifically and efficiently leads to cysteamine (half-cystamine) modification of a single sit
58 ted the extracellular levels of free reduced cysteamine, homocysteine, and cysteine from OHSCs within
59                            Concentrations of cysteamine, homocysteine, and cysteine in the extracellu
60                                              Cysteamine hydrochloride (Cyst), 3-Mercaptopropionic aci
61 d directly using a specific radiolabel, [14C]cysteamine hydrochloride.
62 n situ quantitative estimation of endogenous cysteamine in brain tissue.
63 sed on layer-by-layer assembly was formed by cysteamine in combination with a fourth-generation poly(
64  relies upon the finding that hCBS will take cysteamine in place of L-homocysteine, thereby producing
65               Based on the formation rate of cysteamine in the OHSCs, we obtained the overall apparen
66 of N-acetylating a model compound containing cysteamine in the presence of acetyl-CoA, consistent wit
67 eptide, and subsequent Michael addition with cysteamine increased masses by the predicated 77 and 154
68                                              Cysteamine-induced ulceration in EGF(-/-) mice was used
69                                     In fact, cysteamine is shown to be a potent activator of the enzy
70  bilayer and semi circled DDA on the MPA and cysteamine layers were confirmed by the increased redox
71                                       Plasma cysteamine levels showed diurnal variation, with peak le
72 cystamine also augmented basal intracellular cysteamine levels.
73 opamine by the RNA aptamer, immobilized at a cysteamine-modified Au electrode, and further electroche
74  interactions between the positively charged cysteamine-modified electrode and the negatively charged
75 ence of 1,4-phenylene diisothiocyanate, on a cysteamine-modified gold electrode.
76  be performed by the RNA aptamer tethered to cysteamine-modified gold electrodes via the alkanethiol
77 gold electrodes via carbodiimide coupling to cysteamine-modified gold electrodes.
78 al bilayers was promoted by anchoring of the cysteamine moiety.
79 , heme oxygenase-1, neutrophil infiltration, cysteamine, mucin, hydrogen sulfide, ghrelin, adiponecti
80 e chain elongation intermediates as N-acetyl cysteamine (NAC) thioesters and have used them as substr
81 e synthesis of taurine, the final product of cysteamine oxidation and the second most abundant amino
82 rophage cultures revealed that cystamine and cysteamine possess significant antiviral properties at n
83  with 70 mol % mercaptopropanol and 30 mol % cysteamine/propanedithiol to facilitate membrane fusion
84                  Furthermore, treatment with cysteamine reduced alpha-smooth muscle actin-positive in
85 ults, treatment of cultured macrophages with cysteamine reduced cellular generation of reactive oxyge
86 rs (e.g., DMSO, glycerol, and cationic thiol cysteamine) reduces the incidence of instability after i
87 m and cystamine, diethyl dithiocarbamate and cysteamine, respectively, were found to be ineffective a
88 erestingly, exposure of cells to cysteine or cysteamine resulted in elevated intracellular hypotaurin
89  cystinotic cells' cystine content by use of cysteamine results in normalization of the apoptotic rat
90 unosensor for the detection of MDM2 based on cysteamine self assembled monolayers on a clean polycrys
91  using peptide carriers such as SIGCAFKILGY(-cysteamine) [SIGC(-cysteamine)].
92  specificity for bioorthgonal short N-acetyl cysteamine (SNAc) donors.
93 ite-directed mutagenesis indicate that SIGC(-cysteamine) specifically and efficiently leads to cystea
94 od an aptamer was used to aggregate cationic cysteamine-stabilized CdTe/ZnS core/shell quantum dots,
95  Other antioxidants, approved for human use (cysteamine, succimer, dimercaprol), were not efficacious
96 utants in the presence of a concentration of cysteamine that elicits an intracluster open probability
97  of apoptosis that could be ameliorated with cysteamine, the human cystine depleting therapy.
98                                         Oral cysteamine therapy delays disease progression by reducin
99  investigation into the potential benefit of cysteamine therapy in the treatment of CKD.
100 tment increased, and it decreased as time on cysteamine therapy increased.
101    In a study of renal ischemia reperfusion, cysteamine therapy initiated 10 days after injury and co
102                               Long-term oral cysteamine therapy mitigates these effects.
103 de that serves as a chemical intermediate in cysteamine therapy of cystinosis, and PQLC2 gene silenci
104  adulthood and the effects of long-term oral cysteamine therapy on its nonrenal complications have no
105  who received long-term (> or =8 years) oral cysteamine therapy were taller and heavier, had a renal
106 ucidation of PQLC2 function may help improve cysteamine therapy.
107 eaction of some of its epoxide moieties with cysteamine to afford a monolith rich in surface thiol gr
108 hrough reaction of its epoxide moieties with cysteamine to afford a monolith rich in surface thiol gr
109 were synthesized by first covalently linking cysteamine to docosahexaenoic acid.
110                                           In cysteamine-treated mice, fibrosis severity decreased sig
111 displayed more severe lesions in response to cysteamine treatment compared with wild-type counterpart
112 othyroidism, and death increased as time off cysteamine treatment increased, and it decreased as time
113 viously unrecognized antifibrotic actions of cysteamine via TGF-beta-independent mechanisms that incl
114           Vancomycin/synthetic acyl-N-acetyl cysteamine was not expected to be able to serve as a sur
115 phosphopantetheine, pantetheine, and finally cysteamine was observed with ThnR, ThnH, and ThnT, respe
116 onyl-S-pantetheine or L-threonyl-S-(N-acetyl)cysteamine was used as a small-molecule thioester analog
117 st successful of these biomimetic catalysts (cysteamine) was used to encapsulate firefly luciferase,
118 athione, and the simplest stable aminothiol, cysteamine, we enabled the nanoparticles to exhibit not
119 2+/-0.2 mM for L-serine and 5.6+/-2.2 mM for cysteamine, with kcat = 1.3+/-0.1s(-1) for the formation
120  2.2+/-0.5 mM for L-serine and 6.6+/-2.2 for cysteamine, with kcat = 2.5+/-0.4 s(-1).

WebLSDに未収録の専門用語(用法)は "新規対訳" から投稿できます。
 
Page Top